Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dementia AND Donepezil (Aricept) AND memantine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Dementia AND Donepezil (Aricept) AND memantine. Displaying page 1 of 1.
    EudraCT Number: 2007-001172-36 Sponsor Protocol Number: 2006/123 Start Date*: 2007-08-16
    Sponsor Name:King's College London
    Full Title: Donepezil and Memantine in moderate to severe Alzheimer's Disease
    Medical condition: Moderate to severe alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014810-87 Sponsor Protocol Number: CL2-NEURO-005 Start Date*: 2010-07-22
    Sponsor Name:INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
    Full Title: Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients sufferi...
    Medical condition: - Patients suffering from Mild Cognitive Impairment (memory problems, objective memory disorder, absence of other cognitive disorders or repercussions on daily life, normal general cognitive functi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004918-17 Sponsor Protocol Number: A2501046 Start Date*: 2005-04-01
    Sponsor Name:Pfizer Inc.
    Full Title: A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    7 10012271 VTc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005040-28 Sponsor Protocol Number: 1289.7 Start Date*: 2015-05-11
    Sponsor Name:Boehringer Ingelheim Italia S.p.A.
    Full Title: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compa...
    Medical condition: Cognitive impairment due to Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    18.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) PT (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004888-54 Sponsor Protocol Number: E2020-G000-326 Start Date*: 2007-12-07
    Sponsor Name:Eisai Ltd
    Full Title: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) LT (Completed) ES (Completed) AT (Completed) DK (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004918-14 Sponsor Protocol Number: A2501056 Start Date*: 2008-05-06
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York,NY 10017
    Full Title: A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF DONEPEZIL HYDROCHLORIDE (ARICEPT®) ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH SEVERE ALZHEIMER’S DISEASE
    Medical condition: SEVERE ALZHEIMER’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019858-41 Sponsor Protocol Number: CR100101/CO15570 Start Date*: 2011-02-09
    Sponsor Name:Avraham Pharmaceuticals Ltd.
    Full Title: A 6-month prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate the safety and efficacy of 80mg b.i.d. ladostigil in patients with mild to...
    Medical condition: Patient with mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005263-16 Sponsor Protocol Number: NSC15001 Start Date*: 2016-07-11
    Sponsor Name:Pharmatrophix Inc
    Full Title: A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two d...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:36:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA